AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16935774
Drug: Overexpression of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overexpression of Wnt genes and methylation of Wnt antagonists
Trial: 15823768
Drug: Escin during
RxNorm normalized name: escin
DrugBank: Escin (DB15907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escin during second and third treatment periods
Trial: 15823768
Drug: No escin
RxNorm normalized name: escin
DrugBank: Escin (DB15907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No escin (Control) during first and fourth treatment periods
Trial: 15823768
Drug: Escin treatment
RxNorm normalized name: escin
DrugBank: Escin (DB15907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escin treatment
Trial: 9647368
Drug: Oral midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral midazolam (0.5 mg/kg, maximum 20 mg)
Trial: 22305632
Drug: ATORVA (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATORVA (10, 20, 40, or 80 mg)
Trial: 18276803
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (ADV) 0.14 mg/kg
Trial: 18276803
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (ADV) 0.3 mg/kg
Trial: 16869815
Drug: Adefovir dipivoxil
RxNorm normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adefovir dipivoxil (ADV) 10 mg
Trial: 16467761
Drug: Single immediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single immediate dose of Mitomycin C (MMC)
Trial: 16467761
Drug: Delayed multi-dose
RxNorm normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed multi-dose regimen of Mitomycin C (MMC)
Trial: 12830444
Drug: Conventional thrice-weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional thrice-weekly HD
Trial: 12830442
Drug: Quotidian HD
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / pseudoephedrine hydrochloride Oral Solution [Spantuss HD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quotidian HD therapy
Trial: 10706488
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose inhaled steroids
Trial: 10706488
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose inhaled steroids
Trial: 9322351
Drug: Tropisetron 5
RxNorm normalized name: tropisetron 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 5 mg i.v. on day 1 + 2, then 10 mg p.o.
Trial: 9322351
Drug: Tropisetron 5
RxNorm normalized name: tropisetron 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 5 mg i.v. on day 1 + 2, then 10 mg p.o. + Dexamethasone 20 mg i.v. on days 1 + 2, then 4 mg i.v./p.o.
Trial: 9322351
Drug: Tropisetron 5
RxNorm normalized name: tropisetron 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 5 mg i.v. on day 1 + 2, then 10 mg p.o. + Metoclopramide 20 mg i.v. + 2 x 10 mg p.o. on day 1, then 3 x 10 mg p.o.
Trial: 29198307
Drug: Quetiapine 25
RxNorm normalized name: quetiapine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine 25 mg film-coated tablets
Trial: 29198307
Drug: Control formulation
RxNorm normalized name: nut.tx, weight loss-control formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control formulation of quetiapine 25 mg film-coated tablets
Trial: 19133217
Drug: Maraviroc (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc (300 mg, once or twice per day)
Trial: 16364669
Drug: CS-003 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS-003 (200 mg, solution in distilled water)
Trial: 1564128
Drug: Once-a-day therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-a-day therapy (i.v. dose: 0.8-33 mg/kg; oral dose: 1.6-66 mg/kg)
Trial: 1564128
Drug: Twice-a-day therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-a-day therapy (i.v. dose: 0.8-33 mg/kg; oral dose: 1.6-66 mg/kg)
Trial: 3721055
Drug: Intramuscular buprenorphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular buprenorphine (0.3 mg)
Trial: 3544957
Drug: Intramuscular meperidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular meperidine (75 mg)
Trial: 20955603
Drug: Individualized, nutritional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized, nutritional treatment with energy- and protein-rich supplementation
Trial: 14653300
Drug: bleaching with
RxNorm normalized name: Dioxybenzone/Hydroquinone/Padimate O 30 MG/1 GM-40 MG/1 GM-50 MG/1 GM Topical application Gel/Jelly [HYDROQUINONE SKIN BLEACHING WITH SUNSCREENS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bleaching with gel + 10% sodium ascorbate (SA)
Trial: 14653300
Drug: bleaching with
RxNorm normalized name: Dioxybenzone/Hydroquinone/Padimate O 30 MG/1 GM-40 MG/1 GM-50 MG/1 GM Topical application Gel/Jelly [HYDROQUINONE SKIN BLEACHING WITH SUNSCREENS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bleaching with gel
Trial: 14653300
Drug: bleaching with
RxNorm normalized name: Dioxybenzone/Hydroquinone/Padimate O 30 MG/1 GM-40 MG/1 GM-50 MG/1 GM Topical application Gel/Jelly [HYDROQUINONE SKIN BLEACHING WITH SUNSCREENS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bleaching with gel + 10% butylhydroxyanisole (BHA)
Trial: 14653300
Drug: bleaching with
RxNorm normalized name: Dioxybenzone/Hydroquinone/Padimate O 30 MG/1 GM-40 MG/1 GM-50 MG/1 GM Topical application Gel/Jelly [HYDROQUINONE SKIN BLEACHING WITH SUNSCREENS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bleaching with gel + immersed in artificial saliva for seven days
Trial: 7763124
Drug: Intranasal cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal cocaine (2 mg/kg) and intravenous saline (5 mL/kg)
Trial: 7763124
Drug: Intranasal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal saline (2 mL) and intravenous 10% ethanol (5 mL/kg)
Trial: 7763124
Drug: Intranasal cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal cocaine (2 mg/kg) and intravenous 10% ethanol (5 mL/kg)
Trial: 7763124
Drug: Intranasal (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal (2 mL) and intravenous (5 mL/kg) saline
Trial: 2106127
Drug: Furosemide treatment
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide treatment with high phosphorus intake (1.64 +/- 0.06 mmol/kg per day)
Trial: 2106127
Drug: Furosemide treatment
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide treatment with moderate phosphorus intake (1.24 +/- 0.02 mmol/kg per day)
Trial: 2106127
Drug: Furosemide treatment
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide treatment with low phosphorus intake (0.91 +/- 0.06 mmol/kg per day)
Trial: 1278006
Drug: Furosemide treatment
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide treatment
Trial: 26054881
Drug: Ubiquinol‐10 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinol‐10 (300 mg per day for 48 weeks)
Trial: 26054881
Drug: Ubiquinol‐10 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinol‐10 (300 mg per day for 96 weeks)
Trial: 23810276
Drug: Rosuvastatin/olmesartan 20/40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin/olmesartan 20/40 mg (test formulation)
Trial: 23810276
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg and olmesartan 40 mg (reference formulation)
Trial: 21592475
Drug: Lamivudine in
RxNorm normalized name: Product containing lamivudine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine in the third trimester and postpartum antiviral treatment
Trial: 21592475
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard treatment only)
Trial: 19848566
Drug: Tailored feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored feedback based on cholesterol-related knowledge, attitudes, beliefs, and perceived barriers to medication adherence; 2 additional tailored IVR support calls.
Trial: 8251027
Drug: DL473 twice‐weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL473 twice‐weekly (2HE+L2/7H2L2)
Trial: 8251027
Drug: ARFp twice‐weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARFp twice‐weekly (2HE+R2/7H2R2)
Trial: 8251027
Drug: BRFP daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BRFP daily (2HRE/7HR)
Trial: 2883223
Drug: Oxytetracycline lavage
RxNorm normalized name: Oxytetracycline
DrugBank: Oxytetracycline (DB00595)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytetracycline lavage plus peroperative intravenous metronidazole and cefuroxime
Trial: 29265793
Drug: Intramuscular diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular diclofenac 75 mg + thiocolchicoside 4 mg (FDC)
Trial: 29265793
Drug: Separate injection
RxNorm normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Separate injection of diclofenac and thiocolchicoside (reference)
Trial: 29265793
Drug: Both test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both test and reference treatments
Trial: 23737940
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (5 mg zinc plus riboflavin 0.5 mg/day)
Trial: 23737940
Drug: Placebo (riboflavin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (riboflavin 0.5 mg/day)
Trial: 22980173
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of alprazolam
Trial: 24385131
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of alprazolam
Trial: 16631127
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of diphenhydramine (Benadryl)
Trial: 16631127
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of alprazolam (1 mg)
Trial: 10333379
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg QD)
Trial: 8596376
Drug: CGP 39393
RxNorm normalized name: Leucoflex CGP KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGP 39393 (10 mg)
Trial: 8596376
Drug: CGP 39393
RxNorm normalized name: Leucoflex CGP KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGP 39393 (15 mg)
Trial: 8596376
Drug: CGP 39393
RxNorm normalized name: Leucoflex CGP KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGP 39393 (20 mg)
Trial: 8596376
Drug: Heparin (5000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin (5000 IU three times daily)
Trial: 1822255
Drug: Atropine (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (bolus dose 10 micrograms x kg‐1 followed by a constant-rate infusion of 0.02 microgram x kg‐1 x min‐1)
Trial: 1822255
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of atropine (approximately 1.8‐1.9 mg)
Trial: 22309507
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% 0.4 ml · kg(‐1) plus clonidine 1 μg · kg(‐1) in 1 ml (RC)
Trial: 22309507
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% 0.4 ml · kg(‐1) plus saline in 1 ml (RS)
Trial: 20235224
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockers and cardiac glycosides
Trial: 17667496
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg bolus followed by 2 mg/min infusion for 4 hours postoperatively)
Trial: 16148557
Drug: Oral norfloxacin
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral norfloxacin (25 patients)
Trial: 16148557
Drug: Intravenous ampicillin/sulbactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ampicillin/sulbactam (21 patients)
Trial: 12166344
Drug: Niceritrol 750‐1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niceritrol 750‐1500 mg/day + Pravastatin 10 mg/day (after 8 weeks)
Trial: 12166344
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg/day + Niceritrol 750‐1500 mg/day (after 8 weeks)
Trial: 12166344
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Niceritrol + Pravastatin)
Trial: 8292907
Drug: Cocos nucifera
RxNorm normalized name: COCOS NUCIFERA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocos nucifera pollen extract immunotherapy (CPE‐IT)
Trial: 3052814
Drug: d-fenfluramine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-fenfluramine (30 mg/day)
Trial: 3052814
Drug: d-fenfluramine (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-fenfluramine (single dose of 0, 30, 40, and 60 mg)
Trial: 24796047
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group treated with pinaverium (50 mg, 3 times a day) and live combined bifidobacterium and lactobacillus tablet (4 tablets, 3 times a day) for 4 weeks
Trial: 18208917
Drug: Non-opioid analgesics
RxNorm normalized name: Non-opioid analgesics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-opioid analgesics (n=13)
Trial: 12697633
Drug: Piperacillin-tazobactam, 3.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam, 3.375 g every 6 h
Trial: 15150184
Drug: Ceftriaxone, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone, 1 g once a day
Trial: 12536743
Drug: FU (1
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FU (1 mg.kg‐1) combination with sham infusion
Trial: 12536743
Drug: FU (1
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FU (1 mg.kg‐1) combination with 50 ml of 20% solution of Albumin
Trial: 12536743
Drug: FU (1
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FU (1 mg/kg) combination with 250 ml dextran 40
Trial: 12536743
Drug: FU (1
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FU (1 mg.kg‐1) combination with Albumin
Trial: 12536743
Drug: FU (1
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: FU (1 mg/kg) combination with dextran 40
Trial: 8355942
Drug: Clindamycin vaginal
RxNorm normalized name: clindamycin Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin vaginal cream 2% (5 g intravaginally at bedtime for 7 days)
Trial: 8355942
Drug: Metronidazole 500
RxNorm normalized name: metronidazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 500 mg (two 250-mg capsules orally twice a day for 7 days)
Trial: 8355942
Drug: Clindamycin vaginal
RxNorm normalized name: clindamycin Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin vaginal cream 2%
Trial: 3471750
Drug: Metronidazole 500
RxNorm normalized name: metronidazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 500 mg
Trial: 3549923
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of berberine sulfate (BS) in a single oral dose for ETEC diarrhea
Trial: 3549923
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of berberine sulfate (BS) for ETEC diarrhea
Trial: 3549923
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of berberine sulfate (BS) for cholera
Trial: 3549923
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg of berberine sulfate (BS) plus tetracycline for cholera
Trial: 30167954
Drug: Ilaprazole 20
RxNorm normalized name: ilaprazole
DrugBank: Ilaprazole (DB11964)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilaprazole 20 mg daily for 8 weeks
Trial: 30167954
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg daily for 8 weeks
Trial: 27793818
Drug: Intravenous cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cefazolin and oral ciprofloxacin for 3 days
Trial: 27793818
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin and oral cefuroxime for 3 days
Trial: 11148512
Drug: Nebulized ipratropium
RxNorm normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebulized ipratropium bromide (IB) 250 microg combined with 2.5 mg albuterol by jet nebulization.
Trial: 11148512
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group received isotonic saline solution substituted for IB.
Trial: 9351559
Drug: PSA in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA in combination with digital rectal examination
Trial: 7513718
Drug: 12-h iv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-h iv GH infusion (1 IU/h)
Trial: 7513718
Drug: 2-day sc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-day sc GH treatment (8 IU/day) followed by 12-h iv infusion of GH (1 IU/h)
Trial: 7513718
Drug: Regular daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular daily sc GH therapy (3 IU/m2.day)
Trial: 7513718
Drug: 12-h iv
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-h iv saline infusion
Trial: 7513718
Drug: No GH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No GH (after discontinuation of GH for 2 days)
Trial: 30683087
Drug: COM-B questionnaire
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COM-B questionnaire administered to TB health workers
Trial: 27840330
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (30 mg IV bolus and 1 mg/kg subcutaneous dose)
Trial: 25724860
Drug: Nebulized colistin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized colistin 1 million IU twice a day for one year
Trial: 18334782
Drug: Ropivacaine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (7.5 mg/ml)
Trial: 20171481
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline solution (placebo)
Trial: 10984373
Drug: Budesonide nasal
RxNorm normalized name: budesonide nasal
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide nasal spray and Placebo
Trial: 8799514
Drug: 619C89 (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 619C89 (0.5, 1, 1.5, 2, 2.5 mg kg‐1 loading infusions followed by 0.25, 0.5, 0.75, 1, 1.25 mg kg‐1 maintenance infusions)
Trial: 1847648
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose chemotherapy with cyclophosphamide (10 G m‐2), ifosfamide (11 G m‐2), mitomycin C (70 mg m‐2), mustine (30 mg m‐2)
Trial: 1847648
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose chemotherapy with cisplatin (100 mg m‐2), ifosfamide (11 G m‐2), mitomycin C (70 mg m‐2), mustine (30 mg m‐2)
Trial: 6335905
Drug: Correlation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Correlation of BGP with parathyroid hormone
Trial: 30555165
Drug: Low-dose cytarabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytarabine (LDAC) alone
Trial: 31462554
Drug: Stop NA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop NA therapy for 72 weeks
Trial: 31462554
Drug: Continue NA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue NA therapy for 72 weeks
Trial: 31462554
Drug: Stop NA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stop NA therapy
Trial: 31462554
Drug: Continue NA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue NA therapy
Trial: 30150460
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg MEDI8852 plus 75 mg oseltamivir
Trial: 30150460
Drug: 3,000 mg
RxNorm normalized name: ascorbic acid/minerals 3,000 mg ORAL POWDER IN PACKET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,000 mg MEDI8852 plus 75 mg oseltamivir
Trial: 30150460
Drug: 3,000 mg
RxNorm normalized name: ascorbic acid/minerals 3,000 mg ORAL POWDER IN PACKET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,000 mg MEDI8852 alone